The new research
The aim of the study is to demonstrate the performance of the neuCA15.3 test for monitoring treatment response and/or disease recurrence compared to an FDA cleared CA15-3 test (Roche Elecys CA15-3 II).
Is anyone expecting any significantly different data - we've already been told specificity and sensitivity %'s - what exactly will the new study tell us?
The new researchThe aim of the study is to demonstrate the...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
-0.010(1.75%) |
Mkt cap ! $59.09M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 57.0¢ | 54.0¢ | $96.73K | 176.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 7999 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |